

Priority and watchlist medicines for in-licensing by the Medicines Patent Pool



HIV

lenacapavir

Gilead

broadly neutralising antibodies
for HIV post-natal prophylaxis

Multiple
innovators

cabotegravir & rilpivirine

ViiV & Janssen

cabotegravir ULA

ViiV

doravirine

MSD

GS-1720

Gilead

GS-4182

Gilead

islatravir

Merck

MK-8527

Merck

VH4524184

ViiV



TUBERCULOSIS

quabodepistat

Otsuka

BTZ-043

Univ. of Munich & DZIF

delpazolid

LegoChem BioSciences

ganfeborole

GSK

macozinone

EPFL

sudapyridine

Shanghai Jiatan Biotech



CHILDHOOD ONSET DISEASES

RESPIRATORY SYNCYTIAL VIRUS

nirsevimab

Astrazeneca/Sanofi

clesrovimab

MSD

CYSTIC FIBROSIS

elexacaftor/tezacaftor/ivacaftor

Vertex



VIRAL HEPATITIS

bulevirtide

Gilead



PANDEMIC & EPIDEMIC THREATS

baloxavir marboxil

Roche



DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS

Incretin-based therapies (incl. GLP1 RA)

Multiple innovators

including

semaglutide

Novo Nordisk

orforglipron

Eli Lilly

retatrutide

Eli Lilly

tirzepatide

Eli Lilly

Insulin analogues

Multiple innovators

cardiovascular fixed-dose combination therapies

Multiple innovators



ONCOLOGY

LUNG CANCER

aumolertinib

Revolution Medicines

osimertinib

Astrazeneca

adagrasib

Mirati

lazertinib

Janssen

sotorasib

Amgen

BREAST CANCER

abemaciclib

Eli Lilly

ribociclib

Novartis

trastuzumab SQ

Roche

HAEMATOLOGICAL MALIGNANCIES

ibrutinib

Janssen

zanubrutinib

Beigene

PROSTATE CANCER

apalutamide

Janssen

darolutamide

Bayer

MULTIPLE CANCER INDICATIONS

Immune checkpoint inhibitors

Multiple innovators

including

pembrolizumab

MSD



Scan to access
most recent list of
MPP priorities for in-licensing

PRIORITY LIST

WATCHLIST

October 2024